Accueil

AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects

Study Description: 
Investigational drug AMG 714 will be given to 66 subjects with moderate to severe psoriasis to study safety, pharmacokinetics, and efficacy. Dose levels include 150mg and 300mg and will be given to each subject for a total of 6 doses. Each dose for each subject will be given once every 2 weeks. Subjects will followed for up to 300 days post the first dose of AMG 714.
Maladies et affections de la peau: 
Psoriasis
Study Start Date: 
mars 2007
Estimated completion date: 
avril 2010
Study Location(s): 
Waterloo
Province: 
Ontario
Agegroup: 
18+ years
Gender: 
Both
Healthy Volunteers: 
No
Study Director/Investigator: 
Amgen
Pour nous joindre: 
Amgen Call Center 866-572-6436

Contact Information:

Canadian Skin Patient Alliance
2446 Bank Street, Suite 383
Ottawa, Ontario
K1V 1A8
 

Christine Jackson, Executive Director
phone: 613-422-4265
fax: 613-422- 4267
 

pageTracker._trackPageview();